AMX0035 for ALS – FDA Advisory Committee Update
March 30, 2022 - The FDA convened an Advisory Committee to review the available data supporting AMX0035, a pipeline drug seeking approval for the treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
Download PDF
